Pulse Biosciences Q1 2020 Earnings Report
Key Takeaways
Pulse Biosciences reported a net loss of $11.9 million for Q1 2020, compared to $10.1 million for Q1 2019. Operating expenses increased due to the expansion of operational infrastructure, marketing and sales functions, research and development teams, and clinical trial costs. The company's cash, cash equivalents, and investments totaled $15.9 million as of March 31, 2020.
Completed Pre-Submission meeting with the FDA for the CellFX System for aesthetic dermatology.
Obtained ISO-13485:2016 Quality System Management Certification to prepare for CE Mark filing.
Initiated a rights offering seeking to raise approximately $30 million.
Operations in Q1 2020 experienced minimal impacts as a result of the COVID-19 pandemic.
Pulse Biosciences
Pulse Biosciences
Forward Guidance
Pulse Biosciences acknowledges the uncertain scope and duration of the COVID-19 pandemic, making it difficult to reasonably estimate the future impact on operations and financial results.